自身抗体阴性类风湿关节炎患者中DMARDs的成本-效用比较
本研究基于tREACH试验中2010年标准下中概率层的自身抗体阴性RA患者,比较三种初始治疗策略(iMTX、iHCQ、iGCs)的1年成本-效用。结果显示iHCQ组医疗成本显著低于iGCs组,但出勤主义成本最高;
要点
- iHCQ组医疗成本显著低于iGCs组(P<0.05),但出勤主义成本最高。
- 三种策略的增量成本-效用比无显著差异。
核心结论
- iHCQ医疗成本最低、生产力成本最高,增量成本-效用比不显著,但在荷兰支付意愿阈值下成本-效用概率最高,可作为自身抗体阴性RA患者中iMTX的替代选择,但需验证。
研究设计与样本
- 基于tREACH试验中2010年标准下中概率层的自身抗体阴性RA患者,采用靶向治疗策略(目标低DAS<2.4,每3个月调整治疗),比较三种初始治疗策略的1年成本-效用。
主要发现
- iMTX、iHCQ和iGCs的平均质量调整生命年(标准差)分别为0.71(0.14)、0.73(0.14)和0.71(0.15)。
- iMTX、iHCQ和iGCs的平均总成本(标准差)分别为€10 832(14.763)、€11 208(12.801)和€10 502(11.973)。
- 医疗成本主要由生物制剂成本决定,iHCQ组显著低于iGCs组(P<0.05)。
- 出勤主义成本在iHCQ组最高(55%),其次为iMTX(27%)和iGCs(18%)。
- 增量成本-效用比在治疗策略间无差异;在€50 000支付意愿阈值下,iHCQ成本-效用概率最高(38.7%),其次为iGCs(31.1%)和iMTX(30.2%)。
关键数值与推荐
- 初始治疗策略包括MTX 25 mg/周(iMTX)、iHCQ 400 mg/天或口服糖皮质激素递减方案不用DMARDs(iGCs)。
- 目标为低DAS<2.4,治疗调整每3个月一次。
- 支付意愿阈值为€50 000,即荷兰医疗报销阈值。
临床怎么用
- 对于自身抗体阴性RA患者,iHCQ可作为iMTX的替代选择,但需进一步验证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the 1-year cost-effectiveness between three different initial treatment strategies in autoantibody-negative RA patients, according to 2010 criteria. METHODS: For this analysis we selected all RA patients within the intermediate probability stratum of the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial. The tREACH had a treat-to-target approach, aiming for low DAS <2.4, and treatment adjustments could occur every 3 months. Initial treatment strategies consisted of MTX 25 mg/week (initial MTX, iMTX), iHCQ 400 mg/day or an oral glucocorticoids tapering scheme without DMARDs (iGCs). Data on quality-adjusted life-years, measured with the European Quality of Life 5-Dimensions 3 Levels (EQ-5D-3L), healthcare and productivity costs were used. RESULTS: Average quality-adjusted life-years (s.d.), for iMTX, iHCQ and iGCs were respectively 0.71 (0.14), 0.73 (0.14) and 0.71 (0.15). The average total costs (s.d.) for iMTX, iHCQ and iGCs were, respectively, €10 832 (14.763), €11 208 (12.801) and €10 502 (11.973). Healthcare costs were mainly determined by biological costs, which were significantly lower in the iHCQ group compared with iGCs (P < 0.05). However, costs due to presenteeism were the highest in the iHCQ group (55%) followed by iMTX (27%) and iGCs (18%). The incremental cost-effectiveness ratios did not differ between treatment strategies. At a willingness-to-pay level of €50 000, the Dutch threshold for reimbursement of medical care, iHCQ had the highest probability (38.7%) of being cost-effective, followed by iGCs (31.1%) and iMTX (30.2%). CONCLUSION: iHCQ had the lowest healthcare and highest productivity costs, resulting in a non-significant incremental cost-effectiveness ratio. However, iHCQ had the highest chance of being cost-effective at the Dutch willingness-to-pay threshold for healthcare reimbursement. Therefore, we believe that iHCQ is a good alternative to iMTX in autoantibody-negative RA patients, but validation is needed. CLINICAL TRIAL REGISTRATION NUMBER: ISRCTN26791028.
引用
- Nathalie LM, Mulligen VE, Maria WAEA, et al. Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients. Rheumatology (Oxford). 2021. PMID: 33725091. doi:10.1093/rheumatology/keab251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。